Giuliana Grossi is an editor for The American Journal of Managed Care®, overseeing the publication's Center on Health Equity & Access. Her work focuses on disparities and systemic inequities in care and access to the health system, as well as the impacts of health policy on various racial, gendered, and socioeconomic communities. She seeks perspectives from experts in internal medicine, health equity, community outreach, clinical research, mental health, and legislative policy.
Before Giuliana joined AJMC, she delved into rare disease coverage at HCPLive®, a sister publication, where she fostered connections that extended beyond the research community into that of health advocacy, paving the way to her current role. Her work has been featured in Population Health, Equity & Outcomes® (formerly The American Journal of Accountable Care®), Evidence-Based Oncology®, NewsBreak, CHEST Today, Contemporary Pediatrics, Contemporary OB/GYN, Dermatology Times, Drug Topics, Managed Healthcare Executive, RamaOnHealthcare, and CGTLive.
She received her bachelor's degree in creative writing and psychology from Eckerd College and continued her postgraduate studies at the University of Florida's College of Journalism and Communications.
Rare Blood Disease Innovations Address Unmet Needs, According to ASH Data
Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, with key research presented on immune thrombocytopenia, hemophilia, and multiple myeloma.
New Data Reinforce Iptacopan's Role in Transforming PNH Care With Hemoglobin, QOL Gains
Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan (Fabhalta) as a twice-daily oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who transitioned from anti-C5 therapies.
US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment
While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.
Progression-Free Survival in Relapsed Multiple Myeloma Extended With Ixazomib, Data Show
Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies in improving outcomes, particularly in regions with limited access to chimeric antigen receptor T cells and bispecific antibodies.
Health Equity & Access Weekly Roundup: November 23, 2024
Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Financial, Psychological Burden of Abortion Care in US Raises Calls for Expanded Insurance
There are significant financial and psychological burdens of abortion care in the US, especially for those traveling out of state due to local restrictions in the increasingly restrictive post-Dobbs landscape.
Health Equity & Access Weekly Roundup: November 9, 2024
The health policy implications and ballot measures in the wake of the presidential election, new trends in physician compensation, lessons from the Medicaid unwinding, disparities in cancer mortality, and privately negotiated hospital fees.
Lessons Learned From Medicaid Unwinding as States Tackle Eligibility Checks
Medicaid and CHIP enrollment surged from 71 million in February 2020 to 94 million by April 2023. However, with the pandemic emergency ending in May 2023, states resumed eligibility reviews, initiating a process termed “unwinding.”
Next-Gen Hemophilia Treatments Offer Hope for Joint Health, but Accessibility Challenges Remain
The future of hemophilia care lies not only in technological advancements but also in the pursuit of health equity, ensuring that all patients have access to effective, affordable treatments.
Polycythemia Vera Management: Addressing the Burden of Symptoms and Phlebotomy Dependence
Although polycythemia vera management remains focused on reducing the risk of thrombotic events, there is growing recognition of the need to address the persistent decline in quality of life experienced by many patients.